Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. All News
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
Delayed Japan Exchange  -  02:00 2022-09-30 am EDT
1917.00 JPY   +0.63%
09/30European Medicines Agency Accepts Astellas Marketing Authorization Application for Fezolinetant
AQ
09/29European Medicines Agency Accepts Astellas Pharma Inc. Marketing Authorization Application for Fezolinetant
CI
09/29Lupin Gets US FDA Nod for Overactive Bladder Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about ASTELLAS PHARMA INC.
09/30European Medicines Agency Accepts Astellas Marketing Authorization Application for Fezo..
AQ
09/29European Medicines Agency Accepts Astellas Pharma Inc. Marketing Authorization Applicat..
CI
09/29Lupin Gets US FDA Nod for Overactive Bladder Drug
MT
09/29ASTELLAS PHARMA INC. : Ex-dividend day for interim dividend
FA
09/27US Court Temporarily Bars US Drugmaker Hospira from Launching Generic Version of Astell..
MT
09/20Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start..
AQ
09/12Seagen, Merck, Astellas Release Data From Trial of Padcev, Keytruda to Treat Bladder Ca..
MT
09/12Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (..
CI
09/04Astellas Pharma Inc. Announces Topline Results from Phase 3 Long-Term Safety Study of F..
CI
08/18Astellas Pharma Gets US FDA Nod on New Drug Application for Menopause
MT
08/18ADRs End Lower, Geely Automobile Trades Actively
DJ
08/18U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
CI
08/10Verizon Business selected to transform Astellas Pharma's global network infrastructure
AQ
08/10Verizon Communications Unit Wins Network Management Contract From Astellas Pharma
MT
08/09Astellas Oncology Announces Grand Prize Winner in Annual C3 Prize to Cultivate Innovati..
AQ
08/02Astellas Pharma Shares Sink 3% as Weak Yen Drags Fiscal Q1 Attributable Profit Down
MT
08/02Astellas Pharma Inc. Announces Executive Changes
CI
08/01Transcript : Astellas Pharma Inc., Q1 2023 Earnings Call, Aug 01, 2022
CI
07/31Astellas Pharma : Financial Results (Q1/FY2022)
PU
07/31Astellas Pharma : Presentation Material for Information Meeting (Q1/FY2022)
PU
07/31Astellas Pharma : Supplementary Documents (Q1/FY2022)
PU
07/27Astellas and Seagen Announce Positive Topline Results For PADCEV (enfortumab vedotin-ej..
AQ
07/27Nikkei 225 Up 0.2% Ahead of Federal Reserve Announcement
MT
07/27Japan's Nikkei ends higher helped by chip stocks gains
RE
07/26Japan's Nikkei little changed ahead of Fed meeting outcome
RE
07/26Sector Update: Health Care Stocks Steady Premarket Tuesday
MT
07/26Seagen, Astellas Report Positive Results for Trials on Padcev with Keytruda as Treatmen..
MT
07/26Astellas-Seagen's Bladder Cancer Therapy Shrinks Tumor in Phase 1b/2 Trial
MT
07/26Astellas Pharma : and Seagen Announce Positive Topline Results For PADCEV with KEYTRUDA as..
PU
07/26Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-e..
CI
07/21Astellas Pharma Inc. Unveils Plans to Open New Biotech Campus in South San Francisco
CI
07/21Dolphin Unit Closes $8 Million Purchase of High Reserve F&B in Cash-Stock Deal; Dolphin..
MT
07/05Mogrify and Astellas Announces Collaboration to Conduct Research on in Vivo Regenerativ..
CI
06/28Sutro Biopharma Shares Rise 24% After Collaboration With Astellas Pharma
DJ
06/27Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Nove..
AQ
06/27Sutro Biopharma Shares Soar 67% on Cancer Treatment Collaboration with Astellas
DJ
06/27Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late..
AQ
06/26Astellas Pharma Inc. Announces FDA Update on Fortis Clinical Trial of AT845 in Adults w..
CI
06/23We Published A Story : “Astellas' Path to Sustainability Vol.1: A New Materiality Ma..
PU
06/23Astellas' Path To Sustainability Vol : A New Materiality Matrix as a Compass to Direct our..
PU
06/23Astellas Submits Fezolinetant New Drug Application to U.S. FDA
CI
06/08Astellas Pharma Inc. Celebrates Opening of Large-Scale Gene Therapy Manufacturing Facil..
CI
06/02Nikkei 225 Down 0.2% on Wall Street Cues, Central Bank Outlooks
MT
06/02Japan's Nikkei edges back from 6-week high as Astellas, Sony drag
RE
06/01Japan's Nikkei retreats from 6-week high as Astellas, Sony drag
RE
05/25Astellas Pharma : Posted Notice of Convocation of the 17th Term Annual Shareholders Meetin..
PU
05/25Astellas Pharma : Notice of Convocation of the 17th Term Annual Shareholders Meetingᦀ..
PU
05/24Amphastar Pharmaceuticals Secures FDA Approval for Regadenoson
MT
05/22Astellas Pharma to Appeal US Court Decision on Patent Infringement Lawsuit
MT
05/19Astellas Pharma : Confirms Unfavorable District Court Decision in LEXISCAN® 0.4mg/mL U.S. ..
PU
05/12Astellas Pharma Inc. Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annu..
CI
05/09Twist Bioscience Signs Research Collaboration, Exclusive Option License Deal With Astel..
MT
05/09Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Aste..
CI
05/05Astellas Pharma Inc. to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1™ Tria..
CI
04/27Transcript : Astellas Pharma Inc., 2022 Earnings Call, Apr 27, 2022
CI
04/27Astellas Pharma : Changes of Representative Director and Directors
PU
04/26Astellas Pharma : Financial Results (FY2021)
PU
04/26Astellas Pharma : Supplementary Documents (FY2021)
PU
04/26Astellas Pharma : Presentation Material for Information Meeting (FY2021)
PU
04/26Astellas Oncology Now Accepting Applications for Annual C3 Prize to Cultivate Innovatio..
AQ
04/25The University of Tokyo and Astellas Pharma Inc. Enter Second Phase of Strategic Partne..
CI
04/24Astellas Pharma to Record $389 Million Impairment Loss on Products under Development
MT
04/21Astellas Pharma : Notice Regarding Impairment Loss for Products under Development
PU
04/21Astellas Pharma Inc. Provides Impairment Guidance for the Fourth Quarter Ended March 31..
CI
04/13Astellas Pharma : European Commission Approves PADCEV (enfortumab vedotin) for Locally Adv..
PU
04/13Seagen-Astellas Pharma Treatment for Urothelial Cancer Gets European Commission Nod
MT
04/13Astellas Pharma Inc. and Seagen Inc. Announces European Commission Approves PADCEV™..
CI
04/13European Commission Approves Drug for Urothelial Cancer
DJ
04/11Nikkei 225 Off 0.6% on Russia Outlook, Inflation Concerns
MT
04/07Nikkei 225 Slides 1.97%, Extends Losses on Federal Reserve Outlook; IMF Cuts Japan GDP ..
MT
04/07Japan's Nikkei sinks most in a month on Fed, China worries
RE
04/06Japan's Nikkei hits 3-week low on Fed, China worries
RE
04/05Singlera Genomics Announces Research Collaboration with Astellas Pharma Pursuing Methyl..
CI
04/04We Published A New Sustainability Se : “Developing a sustainable society by leveragi..
PU
04/03Japan's Nikkei falls as chip shares track U.S. peers lower
RE
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on ASTELLAS PHARMA INC.